Replies to post #1074 on Bristol Myers Squibb (BMY)

[lettruthringout]

Certainly BMY never would've parted with China franchise.

[BMY] may be eligible to receive regulatory and sales milestone payments of up to $147.5 million, as well as tiered double-digit royalties on the sale of mavacamten in the [China] territories outlined as part of the collaboration.

Lian is happy to let BMY do all the heavy lifting. Go BMY!